List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11330148/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of four carbapenem-resistant <i>Acinetobacter baumannii</i> outbreaks using Fourier-transform infrared spectroscopy. Infection Control and Hospital Epidemiology, 2023, 44, 991-993.	1.8	6
2	InÂvivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections. Clinical Microbiology and Infection, 2022, 28, 73-78.	6.0	1
3	Effect of a national policy of universal masking and uniform criteria for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) exposure on hospital staff infection and quarantine. Infection Control and Hospital Epidemiology, 2022, 43, 757-763.	1.8	10
4	Carriage of vancomycin-resistant Enterococcus faecium in infants following an outbreak in the neonatal intensive care unit: time to clearance of carriage and use of molecular methods to detect colonization. Infection Control and Hospital Epidemiology, 2022, , 1-4.	1.8	0
5	Large-scale WCS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 934-943.	3.0	5
6	A nationwide population-based study of Escherichia coli bloodstream infections: incidence, antimicrobial resistance and mortality. Clinical Microbiology and Infection, 2022, 28, 879.e1-879.e7.	6.0	16
7	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program. Open Forum Infectious Diseases, 2022, 9, ofab617.	0.9	3
8	Hospital-Onset Bloodstream Infections Caused by Eight Sentinel Bacteria: A Nationwide Study in Israel, 2018–2019. Microorganisms, 2022, 10, 1009.	3.6	5
9	Unraveling the Diversity of Co-Colonization by CPE. Microorganisms, 2022, 10, 1292.	3.6	Ο
10	National Policy for Carbapenem-Resistant <i>Enterobacteriaceae</i> (CRE) Clearance and Discontinuation of Contact Precautions for CRE Carriers in Post–Acute Care Hospitals in Israel: Impact on Isolation-Days and New Acquisitions. Clinical Infectious Diseases, 2021, 72, 829-835.	5.8	4
11	Citrobacter telavivum sp. nov. with chromosomal mcr-9 from hospitalized patients. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 123-131.	2.9	28
12	Surgical antibiotic prophylaxis in patients colonized with multidrug-resistant Gram-negative bacteria: practical and conceptual aspects. Journal of Antimicrobial Chemotherapy, 2021, 76, i40-i46.	3.0	7
13	The effect of prophylaxis with ertapenem versus cefuroxime/metronidazole on intestinal carriage of carbapenem-resistant or third-generation-cephalosporin-resistant Enterobacterales after colorectal surgery. Clinical Microbiology and Infection, 2021, 27, 1481-1487.	6.0	13
14	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. BMC Infectious Diseases, 2021, 21, 309.	2.9	4
15	Antibiotic exposure and the risk of hospital-acquired diarrhoea and <i>Clostridioides difficile</i> infection: a cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2182-2185.	3.0	10
16	The Israeli national policy for discontinuation of isolation of carbapenem-resistant Enterobacterales carriers by carbapenemase type: a retrospective cohort study. Clinical Microbiology and Infection, 2021, 27, 1518.e1-1518.e3.	6.0	3
17	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2533-2541.	2.9	48
18	Evaluation of the MICRONAUT MIC-strip colistin assay for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii and Enterobacterales. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115391.	1.8	2

#	Article	IF	CITATIONS
19	Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infectious Diseases and Therapy, 2021, 10, 1989-2034.	4.0	55
20	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infectious Diseases and Therapy, 2021, 10, 2399-2414.	4.0	15
21	Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa : Implications for Dose Optimization. Antimicrobial Agents and Chemotherapy, 2021, 65, e0120421.	3.2	6
22	Risk of SARS-CoV-2 transmission following exposure during dental treatment – A national cohort study. Journal of Dentistry, 2021, 113, 103791.	4.1	15
23	A multi-institutional outbreak of New Delhi metallo-β-lactamase–producing <i>Escherichia coli</i> with subsequent acquisition of the <i>Klebsiella pneumoniae</i> carbapenemase gene. Infection Control and Hospital Epidemiology, 2021, 42, 1124-1127.	1.8	1
24	Personalized Ertapenem Prophylaxis for Carriers of Extended-spectrum β-Lactamase–producing Enterobacteriaceae Undergoing Colorectal Surgery. Clinical Infectious Diseases, 2020, 70, 1891-1897.	5.8	22
25	Clostridium difficile â€associated disease and Helicobacter pylori seroprevalence: A caseâ€control study. Helicobacter, 2020, 25, e12668.	3.5	2
26	Reply to Wilson et al. Clinical Infectious Diseases, 2020, 71, 1358-1359.	5.8	0
27	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. Clinical Infectious Diseases, 2020, 71, 2599-2607.	5.8	10
28	A National Intervention to Reduce Undesirable Urinary Tract Events in Internal Medicine Wards. Infection Control and Hospital Epidemiology, 2020, 41, s98-s98.	1.8	1
29	Enhanced Humoral Immune Responses against Toxin A and B of Clostridium difficile is Associated with a Milder Disease Manifestation. Journal of Clinical Medicine, 2020, 9, 3241.	2.4	1
30	Integrated chromosomal and plasmid sequence analyses reveal diverse modes of carbapenemase gene spread among <i>Klebsiella pneumoniae</i> . Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25043-25054.	7.1	97
31	Rapid identification of capsulated Acinetobacter baumannii using a density-dependent gradient test. BMC Microbiology, 2020, 20, 285.	3.3	42
32	Elderly bedridden patients with dementia use over one quarter of resources in internal medicine wards in an Israeli hospital. Israel Journal of Health Policy Research, 2020, 9, 21.	2.6	6
33	Fourier Transform Infrared Spectroscopy Is a New Option for Outbreak Investigation: a Retrospective Analysis of an Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae Outbreak in a Neonatal Intensive Care Unit. Journal of Clinical Microbiology, 2020, 58, .	3.9	37
34	A silent outbreak of vancomycin-resistant Enterococcus faecium in a neonatal intensive care unit. Antimicrobial Resistance and Infection Control, 2020, 9, 87.	4.1	12
35	Metagenomic Characterization of Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae Following Treatment with Oral Antibiotics and Fecal Microbiota Transplantation: Results from a Multicenter Randomized Trial. Microorganisms, 2020, 8, 941.	3.6	21
36	In vivo Fitness of Acinetobacter baumannii Strains in Murine Infection Is Associated with International Lineage II-rep-2 and International Lineage III Clones Showing High Case Fatality Rates in Human Infections. Microorganisms, 2020, 8, 847.	3.6	5

#	Article	IF	CITATIONS
37	Detecting carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) carriage: Which body site should be cultured?. Infection Control and Hospital Epidemiology, 2020, 41, 965-967.	1.8	17
38	Performance of Rapid Polymyxinâ"¢ NP and Rapid Polymyxinâ"¢ Acinetobacter for the detection of polymyxin resistance in carbapenem-resistant Acinetobacter baumannii and Enterobacterales. Journal of Antimicrobial Chemotherapy, 2020, 75, 1484-1490.	3.0	6
39	Reply to Apisarnthanarak and Apisarnthanarak. Clinical Infectious Diseases, 2020, 71, 2025-2025.	5.8	0
40	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: inÂvitro synergism is not associated with better clinical outcomes. Clinical Microbiology and Infection, 2020, 26, 1185-1191.	6.0	46
41	Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. ELife, 2020, 9, .	6.0	21
42	Utilising sigmoid models to predict the spread of antimicrobial resistance at the country level. Eurosurveillance, 2020, 25, .	7.0	3
43	Success of a National Intervention in Controlling Carbapenem-resistant Enterobacteriaceae in Israel's Long-term Care Facilities. Clinical Infectious Diseases, 2019, 68, 964-971.	5.8	26
44	Likelihood of persistent carriage of carbapenem-resistant Acinetobacter baumannii on readmission in previously identified carriers. Infection Control and Hospital Epidemiology, 2019, 40, 1188-1190.	1.8	4
45	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. International Journal of Antimicrobial Agents, 2019, 54, 442-448.	2.5	11
46	Trends in antimicrobial resistance in Israel, 2014–2017. Antimicrobial Resistance and Infection Control, 2019, 8, 96.	4.1	15
47	Zero or More: Methodological Challenges of Counting and Estimating Deaths Related to Antibiotic-resistant Infections. Clinical Infectious Diseases, 2019, 69, 2029-2034.	5.8	9
48	Droplet aerosol dissemination of carbapenem-resistant <i>Acinetobacter baumannii</i> surrounding ventilated patients. Infection Control and Hospital Epidemiology, 2019, 40, 365-367.	1.8	9
49	Carriage of Extended-spectrum Beta-lactamase–producing Enterobacteriaceae and the Risk of Surgical Site Infection After Colorectal Surgery: A Prospective Cohort Study. Clinical Infectious Diseases, 2019, 68, 1699-1704.	5.8	44
50	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clinical Infectious Diseases, 2019, 69, 769-776.	5.8	83
51	Antimicrobial use trends, Israel, 2012 to 2017. Eurosurveillance, 2019, 24, .	7.0	12
52	The possibility of transmitting infections with vaginal ultrasound probes: why the guidelines must be met. Israel Medical Association Journal, 2019, 21, 568-569.	0.1	0
53	Colistin versus colistin plus meropenem for severe infections Authors' reply. Lancet Infectious Diseases, The, 2018, 18, 495-496.	9.1	1
54	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . Infection Control and Hospital Epidemiology, 2018, 39, 660-667.	1.8	49

#	Article	IF	CITATIONS
55	Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1281-1288.	2.9	10
56	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 391-400.	9.1	400
57	Lessons From an Outbreak of Varicella Infection in Pediatric Hemato-oncology Patients. Pediatric Infectious Disease Journal, 2018, 37, 649-653.	2.0	13
58	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 318-327.	9.1	3,672
59	<i>Clostridium difficile</i> fecal toxin level is associated with disease severity and prognosis. United European Gastroenterology Journal, 2018, 6, 773-780.	3.8	25
60	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. Clinical Infectious Diseases, 2018, 67, 1815-1823.	5.8	29
61	Does <i>Acinetobacter baumannii</i> Serve as a Source for <i>bla</i> _{NDM} Dissemination into <i>Enterobacteriaceae</i> in Hospitalized Patients?. Microbial Drug Resistance, 2018, 24, 150-153.	2.0	9
62	Israeli National Policy for Carbapenem-Resistant Enterobacteriaceae Screening, Carrier Isolation and Discontinuation of Isolation. Infection Control and Hospital Epidemiology, 2018, 39, 85-89.	1.8	30
63	The impact of antibiotic use on transmission of resistant bacteria in hospitals: Insights from an agent-based model. PLoS ONE, 2018, 13, e0197111.	2.5	55
64	Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study. The Lancet Global Health, 2018, 6, e969-e979.	6.3	89
65	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46
66	EpideMiology and control measures of outBreaks due to Antibiotic-Resistant orGanisms in EurOpe (EMBARGO): a systematic review protocol. BMJ Open, 2017, 7, e013634.	1.9	9
67	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
68	Evolution and dissemination of the Klebsiella pneumoniae clonal group 258 throughout Israeli post-acute care hospitals, 2008–13. Journal of Antimicrobial Chemotherapy, 2017, 72, 2219-2224.	3.0	16
69	Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	149
70	Incidence and Risk Factors for Community and Hospital Acquisition of <i>Clostridium difficile</i> Infection in the Tel Aviv Sourasky Medical Center. Infection Control and Hospital Epidemiology, 2017, 38, 912-920.	1.8	17
71	Carbapenem-Resistant <i>Enterobacteriaceae</i> : A Strategic Roadmap for Infection Control. Infection Control and Hospital Epidemiology, 2017, 38, 580-594.	1.8	74
72	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae – Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 1020-1021.	9.1	10

#	Article	IF	CITATIONS
73	The Impact of a Carbapenem-Resistant Enterobacteriaceae Outbreak on Facilitating Development of a National Infrastructure for Infection Control in Israel. Clinical Infectious Diseases, 2017, 65, 2144-2149.	5.8	12
74	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
75	Gentamicin- and Ciprofloxacin-Resistant Enterobacteriaceae in Cattle Farms in Israel: Risk Factors for Carriage and the Effect of Microbiological Methodology on the Measured Prevalence. Microbial Drug Resistance, 2017, 23, 660-665.	2.0	1
76	Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infectious Diseases, The, 2017, 17, 153-163.	9.1	522
77	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
78	A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. PLoS ONE, 2017, 12, e0171327.	2.5	6
79	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 2016, 6, e009956.	1.9	41
80	Risk Factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) Acquisition Among Contacts of Newly Diagnosed CP-CRE Patients. Infection Control and Hospital Epidemiology, 2016, 37, 1219-1225.	1.8	33
81	Dissemination of the <i>bla</i> _{KPC} gene by clonal spread and horizontal gene transfer: comparative study of incidence and molecular mechanisms. Journal of Antimicrobial Chemotherapy, 2016, 71, 2143-2146.	3.0	33
82	Prevalence and risk factors for carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among patients prior to bowel surgery. Diagnostic Microbiology and Infectious Disease, 2016, 85, 377-380.	1.8	12
83	A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
84	Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infectious Diseases, The, 2016, 16, 661-673.	9.1	327
85	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
86	Molecular types and antimicrobial susceptibility patterns of Clostridium difficile isolates in different epidemiological settings in a tertiary care center in Israel. Diagnostic Microbiology and Infectious Disease, 2016, 86, 450-454.	1.8	7
87	Ceftazidime-avibactam in ceftazidime-resistant infections. Lancet Infectious Diseases, The, 2016, 16, 997-998.	9.1	4
88	Outbreak of adenovirus type 55 infection in Israel. Journal of Clinical Virology, 2016, 78, 31-35.	3.1	33
89	Draft Genome Sequences of Two Multidrug-Resistant Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae Strains Causing Bloodstream Infections. Genome Announcements, 2016, 4, .	0.8	1
90	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41

#	Article	IF	CITATIONS
91	Comparative Study of a Novel Biochemical Assay, the Rapidec Carba NP Test, for Detecting Carbapenemase-Producing Enterobacteriaceae. Journal of Clinical Microbiology, 2016, 54, 453-456.	3.9	22
92	Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. Journal of Antimicrobial Chemotherapy, 2016, 71, 460-463.	3.0	30
93	Cost Analysis of an Intervention to Prevent Methicillin-Resistant Staphylococcus Aureus (MRSA) Transmission. PLoS ONE, 2015, 10, e0138999.	2.5	10
94	Incidence of Carbapenem-Resistant Gram Negatives in Italian Transplant Recipients: A Nationwide Surveillance Study. PLoS ONE, 2015, 10, e0123706.	2.5	68
95	Effect of Resistance Mechanisms on the Inoculum Effect of Carbapenem in Klebsiella pneumoniae Isolates with Borderline Carbapenem Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 5014-5017.	3.2	33
96	Prevalence and risk factors for colonization with methicillin resistant Staphylococcus aureus and other Staphylococci species in hospitalized and farm horses in Israel. Preventive Veterinary Medicine, 2015, 122, 135-144.	1.9	17
97	Prevalence, Risk Factors, and Transmission Dynamics of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: a National Survey of Cattle Farms in Israel in 2013. Journal of Clinical Microbiology, 2015, 53, 3515-3521.	3.9	24
98	Persistence of Klebsiella pneumoniae ST258 as the predominant clone of carbapenemase-producing Enterobacteriaceae in post-acute-care hospitals in Israel, 2008-13. Journal of Antimicrobial Chemotherapy, 2015, 70, 89-92.	3.0	54
99	Mix and match of KPC-2 encoding plasmids in Enterobacteriaceae-comparative genomics. Diagnostic Microbiology and Infectious Disease, 2014, 79, 255-260.	1.8	34
100	An Ongoing National Intervention to Contain the Spread of Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases, 2014, 58, 697-703.	5.8	183
101	Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 1185-1192.	3.0	98
102	Emergence of VIM-producing Aeromonas caviae in Israeli hospitals. Journal of Antimicrobial Chemotherapy, 2014, 69, 1211-1214.	3.0	23
103	Biofilm formation and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2014, 69, 1027-1034.	3.0	63
104	Carbapenemâ€resistant Enterobacteriaceae: biology, epidemiology, and management. Annals of the New York Academy of Sciences, 2014, 1323, 22-42.	3.8	173
105	Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing Klebsiella pneumoniae clone. Diagnostic Microbiology and Infectious Disease, 2014, 78, 12-15.	1.8	31
106	A National Intervention to Prevent the Spread of Carbapenem-Resistant Enterobacteriaceae in Israeli Post-Acute Care Hospitals. Infection Control and Hospital Epidemiology, 2014, 35, 802-809.	1.8	43
107	Combination therapy for carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2014, 69, 2305-2309.	3.0	179
108	Geographical Variability in the Likelihood of Bloodstream Infections Due to Gram-Negative Bacteria: Correlation with Proximity to the Equator and Health Care Expenditure. PLoS ONE, 2014, 9, e114548.	2.5	42

#	Article	IF	CITATIONS
109	Effect of an Investigational Vaccine for Preventing Staphylococcus aureus Infections After Cardiothoracic Surgery. JAMA - Journal of the American Medical Association, 2013, 309, 1368.	7.4	304
110	Systematic Review and Meta-Analysis of <i>In Vitro</i> Synergy of Polymyxins and Carbapenems. Antimicrobial Agents and Chemotherapy, 2013, 57, 5104-5111.	3.2	202
111	Epidemiological and Microbiological Characteristics of an Outbreak Caused by OXA-48-Producing Enterobacteriaceae in a Neonatal Intensive Care Unit in Jerusalem, Israel. Journal of Clinical Microbiology, 2013, 51, 2926-2930.	3.9	36
112	Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance. Clinical Microbiology Reviews, 2013, 26, 289-307.	13.6	141
113	Detection of the plasmid-mediated KPC-2 carbapenem-hydrolysing enzyme in three unusual species of the Enterobacteriaceae family in Israel. Journal of Antimicrobial Chemotherapy, 2013, 68, 719-720.	3.0	21
114	A Swordless Knight: Epidemiology and Molecular Characteristics of the <i>bla</i> _{KPC} -Negative Sequence Type 258 Klebsiella pneumoniae Clone. Journal of Clinical Microbiology, 2012, 50, 3180-3185.	3.9	37
115	Controlling Hospital-Acquired Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE). , 2012, , 105-115.		1
116	Laboratory and Clinical Evaluation of Screening Agar Plates for Detection of Carbapenem-Resistant Enterobacteriaceae from Surveillance Rectal Swabs. Journal of Clinical Microbiology, 2011, 49, 2239-2242.	3.9	106
117	Containment of a Country-wide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in Israeli Hospitals via a Nationally Implemented Intervention. Clinical Infectious Diseases, 2011, 52, 848-855.	5.8	379
118	Predictors of Rectal Carriage of Carbapenem-Resistant Enterobacteriaceae (CRE) among Patients with Known CRE Carriage at Their Next Hospital Encounter. Infection Control and Hospital Epidemiology, 2011, 32, 497-503.	1.8	64
119	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Post-Acute-Care Facilities in Israel. Infection Control and Hospital Epidemiology, 2011, 32, 845-853.	1.8	91
120	Laboratory evaluation of the CHROMagar KPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease, 2011, 70, 565-567.	1.8	27
121	The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagnostic Microbiology and Infectious Disease, 2011, 70, 367-372.	1.8	42
122	Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagnostic Microbiology and Infectious Disease, 2011, 71, 38-45.	1.8	35
123	Dissemination of the Klebsiella pneumoniae Carbapenemase in the Health Care Settings: Tracking the Trails of an Elusive Offender. MBio, 2011, 2, .	4.1	13
124	Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel. Journal of Antimicrobial Chemotherapy, 2011, 66, 672-673.	3.0	42
125	Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism. Journal of Antimicrobial Chemotherapy, 2011, 66, 2763-2766.	3.0	63
126	A Call for Action: The Application of the International Health Regulations to the Global Threat of Antimicrobial Resistance. PLoS Medicine, 2011, 8, e1001022.	8.4	67

#	Article	IF	CITATIONS
127	Molecular Epidemiology, Sequence Types, and Plasmid Analyses of KPC-Producing Klebsiella pneumoniae Strains in Israel. Antimicrobial Agents and Chemotherapy, 2010, 54, 3002-3006.	3.2	79
128	Transfer of Carbapenem-Resistant Plasmid from <i>Klebsiella pneumoniae</i> ST258 to <i>Escherichia coli</i> in Patient. Emerging Infectious Diseases, 2010, 16, 1014-1017.	4.3	126
129	Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain. Journal of Antimicrobial Chemotherapy, 2010, 65, 243-248.	3.0	83
130	The Pivotal Role of Longâ€Term Care Facilities in the Epidemiology ofAcinetobacter baumannii:Another Brick in the Wall. Clinical Infectious Diseases, 2010, 50, 1617-1618.	5.8	16
131	National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by <i>Enterobacteriaceae</i> Producing Extended-Spectrum β-Lactamases. Antimicrobial Agents and Chemotherapy, 2010, 54, 5099-5104.	3.2	125
132	How to stem the tide of carbapenemase-producing Enterobacteriaceae?: proactive versus reactive strategies. Current Opinion in Infectious Diseases, 2010, 23, 327-331.	3.1	63
133	Treatment with Fluoroquinolones or with β-Lactam-β-Lactamase Inhibitor Combinations Is a Risk Factor for Isolation of Extended-Spectrum-β-Lactamase-Producing <i>Klebsiella</i> Species in Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 2010-2016.	3.2	70
134	Complete Nucleotide Sequence of KPC-3-Encoding Plasmid pKpQIL in the Epidemic <i>Klebsiella pneumoniae</i> Sequence Type 258. Antimicrobial Agents and Chemotherapy, 2010, 54, 4493-4496.	3.2	107
135	Carbapenem-Resistant KPC-2-Producing <i>Escherichia coli</i> in a Tel Aviv Medical Center, 2005 to 2008. Antimicrobial Agents and Chemotherapy, 2010, 54, 2687-2691.	3.2	36
136	Worldwide Diversity of <i>Klebsiella pneumoniae</i> That Produce β-Lactamase <i>bla</i> _{KPC-2} Gene1. Emerging Infectious Diseases, 2010, 16, 1349-1356.	4.3	277
137	Molecular Epidemiology of KPC-Producing <i>Klebsiella pneumoniae</i> Isolates in the United States: Clonal Expansion of Multilocus Sequence Type 258. Antimicrobial Agents and Chemotherapy, 2009, 53, 3365-3370.	3.2	494
138	Impact of Quinolone Restriction on Resistance Patterns of <i>Escherichia coli</i> Isolated from Urine by Culture in a Community Setting. Clinical Infectious Diseases, 2009, 49, 869-875.	5.8	110
139	Ertapenem Resistance among Extended-Spectrum-β-Lactamase-Producing <i>Klebsiella pneumoniae</i> Isolates. Journal of Clinical Microbiology, 2009, 47, 969-974.	3.9	57
140	Evaluation of PCR-Based Testing for Surveillance of KPC-Producing Carbapenem-Resistant Members of the <i>Enterobacteriaceae</i> Family. Journal of Clinical Microbiology, 2009, 47, 3261-3265.	3.9	113
141	First Report on a Hyperepidemic Clone of KPC-3-Producing <i>Klebsiella pneumoniae</i> in Israel Genetically Related to a Strain Causing Outbreaks in the United States. Antimicrobial Agents and Chemotherapy, 2009, 53, 818-820.	3.2	156
142	Gramâ€Negative Bacteremia upon Hospital Admission: When Should <i>Pseudomonasaeruginosa</i> Be Suspected?. Clinical Infectious Diseases, 2009, 48, 580-586.	5.8	60
143	Detection of aac(6')-Ib-cr in KPC-producing Klebsiella pneumoniae isolates from Tel Aviv, Israel. Journal of Antimicrobial Chemotherapy, 2009, 64, 718-722.	3.0	34
144	A Multinational Survey of Risk Factors for Infection with Extendedâ€Spectrum Î²â€Łactamase–Producing Enterobacteriaceae in Nonhospitalized Patients. Clinical Infectious Diseases, 2009, 49, 682-690.	5.8	415

#	Article	IF	CITATIONS
145	Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult. International Journal of Infectious Diseases, 2009, 13, e295-e298.	3.3	28
146	Incidence of and Preoperative Risk Factors for <i>Staphylococcus aureus</i> Bacteremia and Chest Wound Infection After Cardiac Surgery. Infection Control and Hospital Epidemiology, 2009, 30, 242-248.	1.8	25
147	Parental Staphylococcus aureus Carriage is Associated With Staphylococcal Carriage in Young Children. Pediatric Infectious Disease Journal, 2009, 28, 960-965.	2.0	33
148	Treatment Options for??Multidrug-Resistant Acinetobacter Species. Drugs, 2008, 68, 165-189.	10.9	49
149	Carbapenem-Resistant Enterobacteriaceae. JAMA - Journal of the American Medical Association, 2008, 300, 2911.	7.4	256
150	Analogous oligoâ€acylâ€lysines with distinct antibacterial mechanisms. FASEB Journal, 2008, 22, 2652-2661.	0.5	61
151	Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrobial Agents and Chemotherapy, 2008, 52, 813-821.	3.2	519
152	Factors Associated with Candidemia Caused by Nonâ€ <i>albicans Candida</i> Species Versus <i>Candida albicans</i> in the Intensive Care Unit. Clinical Infectious Diseases, 2008, 46, 1206-1213.	5.8	226
153	Isolation of Imipenem-Resistant <i>Enterobacter</i> Species: Emergence of KPC-2 Carbapenemase, Molecular Characterization, Epidemiology, and Outcomes. Antimicrobial Agents and Chemotherapy, 2008, 52, 1413-1418.	3.2	179
154	Plasmid-Mediated qnrB2 and Carbapenemase Gene bla KPC-2 Carried on the Same Plasmid in Carbapenem-Resistant Ciprofloxacin-Susceptible Enterobacter cloacae Isolates. Antimicrobial Agents and Chemotherapy, 2008, 52, 2962-2965.	3.2	41
155	Predictors of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality. Antimicrobial Agents and Chemotherapy, 2008, 52, 1028-1033.	3.2	436
156	Dissemination of the CTX-M-25 family Â-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel. Journal of Antimicrobial Chemotherapy, 2008, 62, 289-295.	3.0	40
157	High tigecycline resistance in multidrug-resistant Acinetobacter baumannii—authors' response. Journal of Antimicrobial Chemotherapy, 2007, 60, 178-179.	3.0	6
158	Surveillance Cultures and Duration of Carriage of Multidrug-Resistant Acinetobacter baumannii. Journal of Clinical Microbiology, 2007, 45, 1551-1555.	3.9	154
159	High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2007, 59, 772-774.	3.0	212
160	Mortality and delay in effective therapy associated with extended-spectrum Â-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2007, 60, 913-920.	3.0	527
161	First national surveillance of susceptibility of extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagnostic Microbiology and Infectious Disease, 2007, 57, 201-205.	1.8	26
162	Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant Klebsiella pneumoniae Strains in an Israeli Hospital. Antimicrobial Agents and Chemotherapy, 2007, 51, 3026-3029.	3.2	226

#	Article	IF	CITATIONS
163	Molecular and Epidemiologic Study of Polyclonal Outbreaks of Multidrug-Resistant <i>Acinetobacter baumannii</i> Infection in an Israeli Hospital. Infection Control and Hospital Epidemiology, 2007, 28, 945-950.	1.8	56
164	Raising Standards While Watching the Bottom Line Making a Business Case for Infection Control. Infection Control and Hospital Epidemiology, 2007, 28, 1121-1133.	1.8	125
165	Improved antimicrobial peptides based on acyl-lysine oligomers. Nature Biotechnology, 2007, 25, 657-659.	17.5	238
166	Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in Israel. Antimicrobial Agents and Chemotherapy, 2006, 50, 3098-3101.	3.2	147
167	Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing <i>Enterobacteriaceae</i> . Antimicrobial Agents and Chemotherapy, 2006, 50, 1257-1262.	3.2	382
168	Antimicrobial resistance and patient outcomes: the hazards of adjustment. Critical Care, 2006, 10, 164.	5.8	21
169	Multidrug-Resistant <i>Pseudomonas aeruginosa</i> : Risk Factors and Clinical Impact. Antimicrobial Agents and Chemotherapy, 2006, 50, 43-48.	3.2	527
170	Predictors of Mortality in Patients with Bloodstream Infection Due to Ceftazidime-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2006, 50, 1715-1720.	3.2	74
171	Utility of the VITEK 2 Advanced Expert System for Identification of Extended-Spectrum Â-Lactamase Production in Enterobacter spp Journal of Clinical Microbiology, 2006, 44, 241-243.	3.9	13
172	Endocarditis Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae : Emergence of Resistance to Ciprofloxacin and Piperacillin-Tazobactam during Treatment despite Initial Susceptibility. Antimicrobial Agents and Chemotherapy, 2006, 50, 3179-3182.	3.2	57
173	Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50, 2192-2196.	3.2	50
174	Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Current Opinion in Infectious Diseases, 2005, 18, 306-313.	3.1	194
175	Multidrug-Resistant <i>Acinetobacter baumannii</i> . Emerging Infectious Diseases, 2005, 11, 22-29.	4.3	223
176	Prior Antimicrobial Therapy and Risk for Hospital-Acquired Candida glabrata and Candida krusei Fungemia: a Case-Case-Control Study. Antimicrobial Agents and Chemotherapy, 2005, 49, 4555-4560.	3.2	134
177	Evaluation of an Accelerated Protocol for Detection of Extended-Spectrum β-Lactamase-Producing Gram-Negative Bacilli from Positive Blood Cultures. Journal of Clinical Microbiology, 2005, 43, 439-441.	3.9	5
178	CTX-M-2 and a New CTX-M-39 Enzyme Are the Major Extended-Spectrum Beta-Lactamases in Multiple Escherichia coli Clones Isolated in Tel Aviv, Israel. Antimicrobial Agents and Chemotherapy, 2005, 49, 4745-4750.	3.2	58
179	High Levels of Antimicrobial Coresistance among Extended-Spectrum-β-Lactamase-Producing <i>Enterobacteriaceae</i> . Antimicrobial Agents and Chemotherapy, 2005, 49, 2137-2139.	3.2	140
180	Extended-Spectrum Beta-Lactamases among Enterobacter Isolates Obtained in Tel Aviv, Israel. Antimicrobial Agents and Chemotherapy, 2005, 49, 1150-1156.	3.2	71

#	Article	IF	CITATIONS
181	Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection. International Journal of Molecular Medicine, 2005, 16, 165.	4.0	8
182	The Impact of Methicillin Resistance in <i>Staphylococcus aureus</i> Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges. Infection Control and Hospital Epidemiology, 2005, 26, 166-174.	1.8	792
183	Impact of Severity of Illness Bias and Control Group Misclassification Bias in Case-Control Studies of Antimicrobial-Resistant Organisms. Infection Control and Hospital Epidemiology, 2005, 26, 342-345.	1.8	43
184	The Case-Case-Control Study Design: Addressing the Limitations of Risk Factor Studies for Antimicrobial Resistance. Infection Control and Hospital Epidemiology, 2005, 26, 346-351.	1.8	142
185	Fluoroquinolones Protective against Cephalosporin Resistance in Gram-negative Nosocomial Pathogens. Emerging Infectious Diseases, 2004, 10, 94-99.	4.3	23
186	Reference Group Choice and Antibiotic Resistance Outcomes. Emerging Infectious Diseases, 2004, 10, 1125-1128.	4.3	104
187	Hospitalâ€Acquired Infective Endocarditis: Should the Definition be Broadened?. Clinical Infectious Diseases, 2004, 38, 843-850.	5.8	73
188	Association Between Carriage of <emph type="ITAL">Streptococcus pneumoniae</emph> and <emph TYPE="ITAL">Staphylococcus aureus in Children. JAMA - Journal of the American Medical Association, 2004, 292, 716.</emph 	7.4	261
189	The Magnitude of the Association between Fluoroquinolone Use and Quinolone-Resistant Escherichia coli and Klebsiella pneumoniae May Be Lower than Previously Reported. Antimicrobial Agents and Chemotherapy, 2004, 48, 1934-1940.	3.2	36
190	Reply to Cicalini et al Clinical Infectious Diseases, 2004, 39, 1085-1085.	5.8	33
191	Clycopeptides Are No More Effective than Â-Lactam Agents for Prevention of Surgical Site Infection after Cardiac Surgery: A Meta-analysis. Clinical Infectious Diseases, 2004, 38, 1357-1363.	5.8	134
192	Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. Clinical Microbiology and Infection, 2004, 10, 84-85.	6.0	32
193	Epidemiological interpretation of antibiotic resistance studies – what are we missing?. Nature Reviews Microbiology, 2004, 2, 979-983.	28.6	88
194	Studies of Bloodstream Infection Outcomes: Reading Between the Lines. Infection Control and Hospital Epidemiology, 2003, 24, 884-886.	1.8	12
195	Comparison of Mortality Associated with Methicillinâ€Resistant and Methicillinâ€SusceptibleStaphylococcus aureusBacteremia: A Metaâ€analysis. Clinical Infectious Diseases, 2003, 36, 53-59.	5.8	1,782
196	The Impact of Antimicrobial Resistance on Health and Economic Outcomes. Clinical Infectious Diseases, 2003, 36, 1433-1437.	5.8	504
197	Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species. Antimicrobial Agents and Chemotherapy, 2003, 47, 1882-1886.	3.2	46
198	Occurrence and Phenotypic Characteristics of Extended-Spectrum β-Lactamases among Members of the Family <i>Enterobacteriaceae</i> at the Tel-Aviv Medical Center (Israel) and Evaluation of Diagnostic Tests. Journal of Clinical Microbiology, 2003, 41, 155-158.	3.9	49

#	Article	IF	CITATIONS
199	Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients with <i>Staphylococcus aureus</i> Surgical Site Infection. Clinical Infectious Diseases, 2003, 36, 592-598.	5.8	860
200	Clinical Implications of Varying Degrees of Vancomycin Susceptilibity in Methicillin-ResistantStaphylococcus aureusBacteremia1. Emerging Infectious Diseases, 2003, 9, 657-664.	4.3	42
201	Fluoroquinolones and the Risk for Methicillin-resistant <i>Staphylococcus aureus</i> in Hospitalized Patients1. Emerging Infectious Diseases, 2003, 9, 1415-1422.	4.3	312
202	Antibacterial Properties of Dermaseptin S4 Derivatives with In Vivo Activity. Antimicrobial Agents and Chemotherapy, 2002, 46, 689-694.	3.2	130
203	Effects of Antibiotics on Nosocomial Epidemiology of Vancomycin-Resistant Enterococci. Antimicrobial Agents and Chemotherapy, 2002, 46, 1619-1628.	3.2	148
204	Controlâ€Group Selection Importance in Studies of Antimicrobial Resistance: Examples Applied toPseudomonas aeruginosa,Enterococci, andEscherichia coli. Clinical Infectious Diseases, 2002, 34, 1558-1563.	5.8	163
205	Health and Economic Outcomes of the Emergence of Third-Generation Cephalosporin Resistance in Enterobacter Species. Archives of Internal Medicine, 2002, 162, 185.	3.8	244
206	Health and Economic Outcomes of Vancomycin-Resistant Enterococci. Archives of Internal Medicine, 2002, 162, 2223.	3.8	211
207	Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant <i>Enterococcus</i> . Emerging Infectious Diseases, 2002, 8, 802-807.	4.3	143
208	Methodological Principles of Case-Control Studies That Analyzed Risk Factors for Antibiotic Resistance: A Systematic Review. Clinical Infectious Diseases, 2001, 32, 1055-1061.	5.8	246
209	Clinical Isolation and Resistance Patterns of and Superinfection with 10 Nosocomial Pathogens after Treatment with Ceftriaxone versus Ampicillin-Sulbactam. Antimicrobial Agents and Chemotherapy, 2001, 45, 275-279.	3.2	21
210	Parallel Analysis of Individual and Aggregated Data on Antibiotic Exposure and Resistance in Gramâ€Negative Bacilli. Clinical Infectious Diseases, 2001, 33, 1462-1468.	5.8	153
211	Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among <i>Enterobacter</i> spp. Antimicrobial Agents and Chemotherapy, 2001, 45, 2628-2630.	3.2	153
212	Prolonged Antibiotic Prophylaxis After Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance. Circulation, 2000, 101, 2916-2921.	1.6	503
213	SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens Strains. Antimicrobial Agents and Chemotherapy, 2000, 44, 3035-3039.	3.2	123
214	Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant Escherichia coli in Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2000, 44, 1004-1009.	3.2	58
215	Clinical Significance and Antibiotic Resistance Patterns of <i>Leminorella</i> spp., an Emerging Nosocomial Pathogen. Journal of Clinical Microbiology, 2000, 38, 3036-3038. 	3.9	16
216	Emergence of Antibiotic-Resistant <i>Pseudomonas aeruginosa</i> : Comparison of Risks Associated with Different Antipseudomonal Agents. Antimicrobial Agents and Chemotherapy, 1999, 43, 1379-1382.	3.2	497

#	Article	IF	CITATIONS
217	The Association Between Antecedent Vancomycin Treatment and Hospital-Acquired Vancomycin-Resistant Enterococci. Archives of Internal Medicine, 1999, 159, 2461.	3.8	129
218	Risk Factors for Nosocomial Candiduria Due to <i>Candida glabrata</i> and <i>Candida albicans</i> . Clinical Infectious Diseases, 1999, 29, 926-928.	5.8	86
219	Health and Economic Outcomes of Antibiotic Resistance in Pseudomonas aeruginosa. Archives of Internal Medicine, 1999, 159, 1127.	3.8	298
220	Epidemiology and Clinical Outcomes of Patients with Multiresistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 1999, 28, 1128-1133.	5.8	161
221	Nosocomial Superinfections with Gram-Negative Pathogens and Quinolone Resistance after Treatment with Ciprofloxacin vs Ofloxacin. Drugs, 1999, 58, 128-129.	10.9	Ο
222	Failure of Quality Control Measures To Prevent Reporting of False Resistance to Imipenem, Resulting in a Pseudo-Outbreak of Imipenem-Resistant Pseudomonas aeruginosa. Journal of Clinical Microbiology, 1998, 36, 595-597.	3.9	15
223	Imipenemâ€ResistantPseudomonas aeruginosa: Risk Factors and Antibiotic Susceptibility Patterns. Clinical Infectious Diseases, 1997, 25, 1094-1098.	5.8	159